Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia

Tracy Murphy; Jinfeng Zou; Andrea Arruda; Ting Ting Wang; Zhen Zhao; Yangqiao Zheng; Vikas Gupta; Dawn Maze; Caroline McNamara; Mark D Minden; Aaron Schimmer; Hassan Sibai; Karen Yee; Jose-Mario Capo-Chichi; Tracy Stockley; Andre Schuh; Scott V Bratman; Steven M Chan

doi:10.3324/haematol.2023.283510

Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia

Haematologica. 2024 Feb 1;109(2):671-675. doi: 10.3324/haematol.2023.283510.

Authors

Tracy Murphy¹, Jinfeng Zou¹, Andrea Arruda¹, Ting Ting Wang¹, Zhen Zhao¹, Yangqiao Zheng¹, Vikas Gupta¹, Dawn Maze¹, Caroline McNamara², Mark D Minden¹, Aaron Schimmer¹, Hassan Sibai¹, Karen Yee¹, Jose-Mario Capo-Chichi³, Tracy Stockley³, Andre Schuh¹, Scott V Bratman¹, Steven M Chan⁴

Affiliations

¹ Princess Margaret Cancer Center, University Health Network, Toronto, Ontario.
² Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
³ Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; Laboratory Medicine Program, University Health Network, Toronto, ON.
⁴ Princess Margaret Cancer Center, University Health Network, Toronto, Ontario. steven.chan@uhnresearch.ca.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Isocitrate Dehydrogenase* / genetics
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / genetics
Mutation
Neoplasm, Residual / diagnosis
Neoplasm, Residual / genetics
Prognosis
RNA Splicing Factors / genetics

Substances

RNA Splicing Factors
Isocitrate Dehydrogenase

Grants and funding

Funding: This work was supported by a Collaborative Personalized Cancer Medicine Team Grant from the Princess Margaret Cancer Foundation and an Acute Leukemia Translational Research Initiative Grant from the Ontario Institute for Cancer Research.